Skip to main content
SpringerLink
Log in

Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate

  • Case Report
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Chronic myeloid leukemia (CML) in blast crisis has a dismal prognosis. Imatinib mesylate (IM) is a new drug which has been shown to induce complete hematological remission in 55% and complete cytogenetic response in 22% of the patients with CML in blast crisis.

Methods

A child with CML in lymphoid blast crisis was diagnosed by complete hematological and bone marrow examination. There was no central nervous system (CNS) leukemia at presentation. The child was treated with IM at a daily dose of 400 mg.

Results

The child showed remission after IM administration for 28 days and remained in remission till 59 days. On day 59 she experienced headache and vomiting. Results of cerebrospinal fluid taken for cytopathology showed CNS leukemia. MCP 841 protocol for ALL and weekly intrathecal triple therapy (ITT) was given.

Conclusions

Along with IM treatment in patients with CML in blast crisis, weekly ITT with hydrocortisone, cytosine arabinoside and methotrexate should be recommended to prevent CNS involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. FDA Approves Gleevec for leukemia treatment. FDA Consum 2001;35:6.

    Google Scholar 

  2. Champagne MA, Capdeville R, Kralio M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (ST1571) for treatment of children with philadelphia chromosome-positive leukemia: results from a children’s oncology group phase I study. Blood 2004;104:2655–2660.

    Article  PubMed  CAS  Google Scholar 

  3. Kantarjian H, Sawyers C, Hochhaus A, Guilhol F, Schiffer C, Gambacorti-Passerini C, et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.

    Article  PubMed  CAS  Google Scholar 

  4. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate (Glivec) in patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2002;100:1965–1971.

    Article  Google Scholar 

  5. Griffin JD, Todd RF 3rd, Ritz J, Nadler LM, Canellos GP, Rosenthal D, et al. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 1983;61:85–91.

    PubMed  CAS  Google Scholar 

  6. Bakhshi A, Minowada J, Arnold A, Cossman J, Jensen JP, Whang-Peng J, et al. Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. N Engl J Med 1983;309:829–834.

    Google Scholar 

  7. Derderian PM, Kantarjian HM, Talpaz M, O’Brien S, Cork A, Estey E, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristic, treatment response and prognosis. Am J Med 1993;94:69–72.

    Article  PubMed  CAS  Google Scholar 

  8. Leis JF, Stephan DE, Curtain PT, Ford JM, Peng B, Schubach S, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and philadelphia chromosome positive acute lymphoblastic leukemia treated with Imatinib ST-1571. Leuk Lymphoma 2004;45:695–698.

    Article  PubMed  CAS  Google Scholar 

  9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng J Med 2001;344:1038–1042.

    Article  CAS  Google Scholar 

  10. Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of Imatinib mesylate and its N-desmethylated metabolite in cerebrospinal fluid. Ann Hematol 2004;83:401–402.

    Article  PubMed  Google Scholar 

  11. Pfeifer H, Wassmann B, Hofmann W-K, Komor M, Scheuring U, Bruck P, et al. Risk and prognosis of central nervous system leukemia in patients with phildelphia chromosomepositive acute leukemias treated with Imatinib mesylate. Clin Cancer Res 2003;9:4674–4681.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Oncology Division, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Vasantha Thavaraj & Rachna Seth

Authors
  1. Vasantha Thavaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachna Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasantha Thavaraj.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thavaraj, V., Seth, R. Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World J Pediatr 4, 145–147 (2008). https://doi.org/10.1007/s12519-008-0029-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-008-0029-3

Key words

Search

Navigation